TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

This study is testing a combination approach for liver cancer (hepatocellular carcinoma, or HCC) with a specific type of tumor blood vessel invasion (portal vein tumor thrombus). The combination includes chemoembolization (TACE), immunotherapy (atezolizumab), targeted therapy (bevacizumab), and radioactive seed implants (I-125 brachytherapy). **You may be eligible if:** - You are 18–75 years old with a confirmed diagnosis of liver cancer (HCC) - Your cancer involves a portal vein tumor thrombus of Type I or II - Your liver function is adequate (Child-Pugh class A) - Your overall health is good (ECOG score 0–1) - You have not previously received systemic treatment for HCC **You may NOT be eligible if:** - Your liver cancer is diffuse (spread throughout the entire liver) or has spread outside the liver - You have bleeding disorders or uncontrolled esophageal/stomach varices - You have a history of organ transplant - You are pregnant or breastfeeding - You have a history of autoimmune disease or immune deficiency Talk to your doctor to see if this trial is right for you.